IPHA
Innate PharmaNASDAQ
Healthcare • Biotechnology
Updated 1 day ago
Coverage limited
Factor tilt: Anti-Value Micro Cap
$1.47-0.68%
Close Oct 13, 2026
- Market cap
- $134.38M
- 1 month
- -20.5%
- 3 months
- -18.3%
- 1 year
- -27.6%
- 52-week range
- $1.17$2.54
- Dividend
- No dividends on record
- Short interest
- 0.1% of float88.6K shares · settled Sep 30, 2026 · +16.5% since Sep 15, 2026 · FINRA
End-of-day close from stored market data, not a live quote.
Portfolio context
Sign in to see your position size
We’ll show you if IPHA is in your portfolio and how much it contributes.
Sign inMarket context
Loading market dates
No upcoming ex-dividend date announced
No 8-K filings in the last 30 days.
Smart money context
Holder IQ: MEDIUM
2 top institutions tracked
as of 2026-Q2 (filed 2026-09-02)
Last 13F trend: unchanged (light)
Unlock crowding heatmapUnlock filer discoveryInsider context
Sentiment: unknown
No recent insider trades detected.
Red flags: 0
Largest 13-F holders · Q2 2026
10 filers reported a long position in IPHA for Q2 2026. 13-F holdings are filed up to 45 days after the quarter ends.
| Holder | Value | Shares | Shares vs Q1 2026 |
|---|---|---|---|
| Lion Point Capital, LP | $149.3K | 81.2K | Unchanged |
| MORGAN STANLEY | $80.1K | 43.5K | Unchanged |
| SmartHarvest Portfolios, LLC | $43.7K | 23.8K | New |
| XTX Topco Ltd | $27.8K | 15.1K | New |
| CITADEL ADVISORS LLC | $22.9K | 12.4K | New |
| JANE STREET GROUP, LLC | $19K | 10.3K | -76.2% |
| RHUMBLINE ADVISERS | $8.7K | 4.7K | -0.3% |
| UBS Group AG | $2.5K | 1.4K | +58.3% |
| Farther Finance Advisors, LLC | $38 | 21 | +110% |
| GAMMA Investing LLC | $17 | 9 | -96.3% |
Get the Full Analysis for IPHA
Unlock detailed insider transactions, institutional holder changes, factor exposures, and personalized alerts. Start free with your own portfolio.